Method for treating diabetes using neurturin
The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
1. A method for lowering blood glucose levels in a mammal having impaired beta cell function, comprising administering neurturin product to the mammal in an amount sufficient to increase neurturin concentration relative to an untreated mammal having impaired beta cell function, wherein blood glucose levels in the mammal administered the neurturin product are lowered; wherein the biologically active neurturin product comprises a biologically active neurturin polypeptide; wherein the biologically active neurturin polypeptide is capable of dimerizing with another neurturin polypeptide; and wherein the neurturin polypeptide shares at least 90% sequence identity with:
a) the human neurturin precursor protein having the amino acid sequence set forth in SEQ ID NO: 7; or
b) the mature neurturin protein product that results from the cleavage of the human neurturin protein precursor having an amino acid sequence set forth in SEQ ID NO: 7.
2. The method of claim 1 , wherein the neurturin product is administered directly to a pancreas.
3. The method of claim 1 , wherein the biologically active neurturin polypeptide shares at least 95% sequence identity with:
a) the human neurturin precursor protein having the amino acid sequence set forth in SEQ ID NO: 7; or
b) the mature neurturin protein product that results from the cleavage of the human neurturin protein precursor having an amino acid sequence set forth in SEQ ID NO: 7.
4. The method of claim 3 , wherein the biologically active neurturin polypeptide shares 100% sequence identity with:
a) the human neurturin precursor protein having the amino acid sequence set forth in SEQ ID NO: 7; or
b) the mature neurturin protein product that results from the cleavage of the human neurturin protein precursor having an amino acid sequence set forth in SEQ ID NO: 7.
5. The method of claim 1 , wherein the mammal having impaired beta cell function suffers from diabetes type I.
6. The method of claim 1 , wherein the mammal having impaired beta cell function suffers from diabetes type II.
7. The method of claim 1 , wherein the mammal having impaired beta cell function suffers from latent autoimmune diabetes in adults.